Is tenofovir alafenamide fumarate tablets/Veride harmful to the kidneys?

Tenofovir alafenamide fumarate (TAF) is a drug used to treat hepatitis B. Its main component is tenofovir alafenamide, which is a nucleoside reverse transcriptase inhibitor. Cases of kidney damage have been reported with products containing tenofovir alafenamide fumarate (TAF). These cases include acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome. Although other potential confounders were present in most of these cases that may have contributed to the reported renal events, these factors may also predispose patients to tenofovir-related adverse events.

Therefore, serum creatinine, estimated creatinine clearance, urine glucose, and urine protein need to be assessed in all patients before initiating treatment with tenofovir alafenamide, at the initiation of treatment, and during treatment on a clinically appropriate schedule. In patients with chronic kidney disease, serum phosphorus levels also need to be assessed. If there is a clinically significant decrease in renal function or evidence of Fanconi syndrome, treatment with tenofovir alafenamide should be discontinued.

Tenofovir prodrug patients with impaired renal function and patients taking nephrotoxic substances, including NSAIDs, are at increased risk for renal-related adverse reactions. Based on current research and clinical experience, Veride is associated with a relatively small risk of kidney damage and is even considered to have a lower risk of nephrotoxicity than other anti-hepatitis B drugs.

In short, tenofovir alafenamide fumarate tablets cause relatively little damage to the kidneys. However, it is still necessary to pay close attention to the patient's renal function changes during use and follow the doctor's instructions. If patients have any concerns about the safety and kidney risks of medications, please consult a professional physician for individualized advice and guidance.